Table 3.
Summary of Ongoing Clinical Trials With RET Kinase Inhibitor for the Treatment of Patients With RET Fusion–Positive NSCLCa
| Trials | Status | RET Inhibitor | ClinicalTrials.gov Identifier |
|---|---|---|---|
| AcceleRET lung study of pralsetinib for the first-line RET fusion–positive, metastatic NSCLC (phase 3) | Recruiting | Pralsetinib (BLU-667) | NCT04268550 |
| Phase 1/2 study of the highly selective RET inhibitor, pralsetinib (BLU-667), in patients with thyroid cancer, NSCLC, and other advanced solid tumors | Recruiting | Pralsetinib (BLU-667) | NCT04222972 |
| Phase 1/2 study of the highly selective RET inhibitor, pralsetinib (BLU-667), in patients with thyroid cancer, NSCLC, and other advanced solid tumors | Recruiting | Pralsetinib (BLU-667) | NCT03037385 |
| Targeted treatment for RET fusion–positive advanced NSCLC cancer (a LUNG-MAP treatment trial) | Recruiting | Selpercatinib (LOXO-292) | NCT03037385 |
| Phase 1/2 study of LOXO-292 in patients with advanced solid tumors, RET fusion–positive solid tumors, and MTC | Recruiting | Selpercatinib (LOXO-292) | NCT03157128 |
| A study of Selpercatinib (LY3527723) in participants with advanced or metastatic RET fusion–positive NSCLC (LIBRETTO-431; phase 3) | Recruiting | Selpercatinib (LOXO-292) | NCT04194944 |
| Study of TPX-0046, A RET/SRC inhibitor in adult subjects with advanced solid tumors harboring RET fusions or mutations | Recruiting | TPX-0046 | NCT04161391 |
| ALEctinib for the treatment of pretreated RET-rearranged advanced NSCLC | Recruiting | Alectinib | NCT03445000 |
MTC, medullary thyroid cancer.
a
Details of this table were accessed on April 28, 2020.